Takeda has entered an option agreement with Ascentage Pharma to exclusively license olverembatinib, a therapy for chronic myeloid leukemia and other blood cancers.
Should the option be exercised, Takeda may get global rights to develop and market olverembatinib outside Mainland China and certain other territories. In return, Ascentage would receive a USD 100 million upfront payment and a minority equity investment from Takeda plus potential milestone payments and royalties upon successful regulatory approval. Ascentage will continue to oversee the clinical development of olverembatinib, which is in Phase III trials.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.